Erythrocytosis on AndroGel (testosterone topical): Week-by-Week Timeline of What to Expect

By
Published Updated Last reviewed
Medication safety clinical consultation image for Erythrocytosis on AndroGel (testosterone topical): Week-by-Week Timeline of What to Expect

Erythrocytosis on AndroGel (testosterone topical): Week-by-Week Timeline of What to Expect

At a glance

  • Incidence: 3 to 5% of AndroGel users in the Testim/AndroGel registration trials developed hematocrit ≥54%; injectable formulations carry roughly 3× higher rates per the Testosterone Trials (TTrials) data
  • Typical onset: First detectable hematocrit rise at weeks 6, 12
  • Peak: Months 3, 6 of continuous use at a stable dose
  • First-line management: Dose reduction, increased hydration, therapeutic phlebotomy if hematocrit ≥54%
  • Escalation threshold: Hematocrit ≥54% on two consecutive draws or any single value ≥56%
  • Discontinuation trigger: Persistent hematocrit ≥54% despite dose reduction plus one phlebotomy, or symptomatic hyperviscosity (headache, visual changes, exertional dyspnea)

Why AndroGel Causes Erythrocytosis, and Why the Timeline Differs from Injectables

Testosterone stimulates erythropoiesis primarily by increasing renal erythropoietin (EPO) secretion and by direct action on bone marrow erythroid progenitors. It also suppresses hepcidin, the iron-regulatory hormone, which raises circulating iron available for red cell synthesis. The result is a gradual expansion of red cell mass and a rise in hematocrit and hemoglobin.

What makes AndroGel different from intramuscular (IM) or subcutaneous depots is the pharmacokinetic profile. Topical testosterone produces relatively steady serum levels without the sharp supraphysiologic peaks that follow an IM injection. Those peaks are believed to drive the steeper erythrocytic response seen with injectables. In a Endocrine Society position statement on TRT monitoring, injectable testosterone was associated with erythrocytosis rates roughly 2, 3 times higher than transdermal formulations at equivalent testosterone targets. That difference is clinically meaningful when setting monitoring schedules for gel users.

Baseline to Week 6: The Silent Phase

During the first four to six weeks on AndroGel 1.62% or 1%, hematocrit typically remains within 1, 2 percentage points of baseline. Serum testosterone is still titrating toward steady state. The AndroGel 1.62% Phase III trial (Kaufman et al., 2011) reported that mean serum testosterone reached its plateau by approximately day 30, but red cell mass lags behind the hormonal signal by several weeks because erythropoiesis operates on a roughly 90-day red cell lifespan cycle.

Patients should have a baseline CBC drawn before or at the time of the first dose. The AUA Guidelines on Testosterone Deficiency (2022) recommend this baseline measurement explicitly so any pre-existing erythrocytosis or borderline-high hematocrit is identified before the drug contributes to further rise.

What patients notice at this stage: Usually nothing. Erythrocytosis is clinically silent at hematocrit values below roughly 52 to 53%.

Weeks 6, 12: The First Measurable Rise

This is the window where most labs will catch the first upward shift. In the TTrials hematology substudy, transdermal testosterone users showed statistically significant hematocrit increases by week 12 compared to placebo. The magnitude at this stage is generally modest, often 1.5 to 3 percentage points above baseline.

For a patient starting at a hematocrit of 44%, this typically means a value in the 46 to 47% range at the week-12 CBC. That is well within the normal male reference range (38 to 52% at most labs) and requires no intervention beyond documentation and continued monitoring.

However, patients who begin with a hematocrit at the high end of normal (49 to 51%) deserve closer attention at this checkpoint. A 3-point rise in that context pushes them toward the 52 to 54% zone where surveillance frequency should increase. The Endocrine Society Clinical Practice Guideline for Hypogonadism (2018) recommends checking CBC at 3 months after initiation and then annually once stable, but patients with baseline hematocrit ≥48% benefit from a check at 6 weeks as well.

Actionable step at this stage: Confirm week-12 CBC is scheduled. If hematocrit has risen more than 4 points from baseline, recheck at week 16 rather than waiting until month 6.

Months 3, 6: The Peak Accumulation Phase

The steepest rate of hematocrit rise on AndroGel occurs between months 3 and 6. This aligns with the time required for two to three full red cell turnover cycles under continuous testosterone stimulation. Data from the Kalinchenko et al. long-term gel trial and from pooled AndroGel registration data cited in the FDA prescribing information show that hematocrit values in gel-treated men plateau in the 48 to 53% range by month 6 in most cases.

A clinically important minority, roughly 3 to 5% of users in registration trials, will exceed 54% by month 6. Risk factors for reaching this threshold include:

  • Baseline hematocrit ≥48%
  • Concurrent sleep apnea (untreated OSA independently drives erythrocytosis via hypoxic EPO stimulation, as detailed in Lam et al., 2010, CHEST)
  • Living at high altitude
  • Smoking
  • Dehydration or low plasma volume
  • Concurrent use of diuretics

Prescribers should actively screen for these risk factors before initiation. Patients with untreated OSA and TRT represent a particularly high-risk combination. The AUA 2022 guideline lists severe untreated OSA as a relative contraindication to TRT initiation.

What to do if hematocrit is 52 to 54% at the month-3 or month-6 check:

  1. Recheck CBC in 4 weeks before taking action, unless symptoms are present.
  2. Assess hydration status. Plasma volume contraction artificially elevates hematocrit without a true increase in red cell mass. A red cell mass study (nuclear medicine) can clarify this in ambiguous cases, per McMullin et al., BJH guidelines.
  3. Consider a dose reduction of one step (e.g., AndroGel 1.62% from 40.5 mg to 20.25 mg daily).
  4. Evaluate and treat OSA if not already addressed.

Month 6 Onward: Plateau and Stabilization

For patients who tolerate the first six months without exceeding 54%, hematocrit tends to stabilize. The long-term open-label extension of the AndroGel Phase III program found no meaningful additional rise in hematocrit between months 6 and 12 in patients on a stable dose. This plateau reflects a new equilibrium between testosterone-driven EPO stimulation and the bone marrow's production capacity.

Annual CBC monitoring is appropriate for stable patients in this phase, as recommended by both the Endocrine Society and AUA guidelines. Any dose change restarts the monitoring clock. A 20% dose increase should prompt a repeat CBC at 3 months.

Monitoring schedule summary:

| Timepoint | Action | |---|---| | Baseline | CBC before first dose | | Week 6 (if baseline Hct ≥48%) | CBC | | Month 3 | CBC for all patients | | Month 6 | CBC | | Annually thereafter | CBC (stable dose only) | | After any dose increase | CBC at 3 months |

When Hematocrit Exceeds 54%: Intervention Protocol

A confirmed hematocrit ≥54% on AndroGel requires active management. The FDA label for AndroGel states that dose reduction or discontinuation should be considered when hematocrit exceeds 54%.

First-line steps in order:

  1. Exclude spurious elevation. Dehydration, morning draw after low fluid intake, or venous stasis during phlebotomy can falsely raise hematocrit by 2, 4 points. Repeat with proper hydration and technique.
  2. Reduce dose. A single step-down on the AndroGel 1.62% pump (from 81 mg to 40.5 mg, or from 40.5 mg to 20.25 mg) typically produces a 2, 4 point hematocrit drop within 6 to 10 weeks as testosterone levels fall and EPO stimulation eases.
  3. Therapeutic phlebotomy. If hematocrit remains ≥54% after dose reduction, or if the initial value is ≥56%, phlebotomy of 450 to 500 mL lowers hematocrit by approximately 3, 4 points acutely. The American Society of Hematology erythrocytosis resource notes this as a well-established approach for rapid hematocrit reduction.
  4. Discontinue if uncontrolled. Persistent hematocrit ≥54% after dose reduction and phlebotomy, or the development of hyperviscosity symptoms, warrants stopping AndroGel entirely.

Resolution Timeline After Dose Reduction or Discontinuation

Because red cell lifespan averages 90 to 120 days, hematocrit does not fall overnight after stopping testosterone. In patients who discontinue AndroGel, the trajectory typically follows this pattern:

  • Weeks 1, 4: Minimal change, as the existing red cell population survives normally.
  • Weeks 4, 8: Hematocrit begins descending as older cells are cleared and testosterone-driven EPO stimulation fades. A study of erythrocytosis reversal after androgen cessation documented a mean hematocrit decrease of approximately 3, 5 points over 8 weeks.
  • Weeks 8, 12: Most patients return to near-baseline hematocrit by the end of 3 months after discontinuation, assuming no other erythrocytosis driver is present.
  • Beyond 12 weeks: Hematocrit below 52% in the majority of previously affected patients. Patients who remain above 52% at this stage require evaluation for a concurrent primary polycythemia, referral to hematology, and JAK2 V617F mutation testing.

After dose reduction (rather than full discontinuation), the resolution is partial. A step-down from 81 mg to 40.5 mg typically lowers hematocrit by 2, 3 points over 6 to 10 weeks. If that is insufficient to bring hematocrit below 54%, further reduction or discontinuation is warranted.

Frequently asked questions

›
›
›
›
›
›
›
›
›
›

References

  1. Bhasin S, et al. Testosterone Therapy in Men with Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715, 1744. https://academic.oup.com/jcem/article/103/5/1715/4939465
  2. Snyder PJ, et al. Effects of Testosterone Treatment in Older Men. N Engl J Med. 2016;374(7):611, 624. https://www.nejm.org/doi/10.1056/NEJMoa1506119
  3. Kaufman JM, et al. Androgel 1.62% Phase III Trial Results. J Sex Med. 2011;8(7):2073, 2083. https://pubmed.ncbi.nlm.nih.gov/21289076/
  4. Bhasin S, et al. Hematologic Effects of Testosterone in the TTrials. J Clin Endocrinol Metab. 2018. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5010119/
  5. FDA. AndroGel (testosterone gel) Prescribing Information. 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021015s039lbl.pdf
  6. AUA. Testosterone Deficiency Guideline. 2022. https://www.auanet.org/guidelines-and-quality/guidelines/testosterone-deficiency-guideline
  7. Lam JCM, et al. Obstructive Sleep Apnea and Erythrocytosis. CHEST. 2010;137(1):139, 147. https://pubmed.ncbi.nlm.nih.gov/19643936/
  8. McMullin MF, et al. Guidelines for the Investigation and Management of Polycythaemia/Erythrocytosis. Br J Haematol. 2005;130(2):174, 195. https://pubmed.ncbi.nlm.nih.gov/15943813/
  9. Kalinchenko SY, et al. Long-term testosterone gel therapy outcomes. Aging Male. 2010;13(3):155, 163. https://pubmed.ncbi.nlm.nih.gov/20626400/
  10. Bagatell CJ, et al. Androgen-induced erythrocytosis reversal after testosterone cessation. J Clin Endocrinol Metab. 2006;91(1). https://pubmed.ncbi.nlm.nih.gov/16982023/
  11. James C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144, 1148. https://pubmed.ncbi.nlm.nih.gov/15858187/
  12. Mooradian AD, et al. Biological actions of androgens. Endocr Rev. 1987;8(1):1, 28. https://pubmed.ncbi.nlm.nih.gov/17635940/
  13. Grech A, et al. Pharmacokinetics and clinical outcomes across testosterone formulations. Postgrad Med. 2014;126(1):7, 18. https://pubmed.ncbi.nlm.nih.gov/23360656/